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ABSTRACT 
Diabetes is associated with metabolic and functional alterations in the gut. Using an experimental model 
of streptozotocin (STZ)-induced diabetes in rodents, we analyzed the extracellular matrix (ECM) and 
TGF-β/Smad signaling in the colon mucosa. Male rats were divided into normal control, diabetic and 
insulin treated diabetic groups during 4 and 9 weeks. Sirius red staining showed marked increase in the 
extracellular matrix deposition in diabetic mucosa. High levels of fibrillar collagen (I and III) and 
fibronectin mRNAs were also detected with an imbalance between MMPs/TIMPs activities. Moreover, an 
increased mesenchymal cell proliferation together with an enhanced expression of myofibroblasts 
markers vimentin and α-SMA were observed. TGF-β/Smad signaling-related genes were determined 
using RT-PCR, western blotting, and immunohistochemistry. Diabetic rats showed a significant up-
regulation of TGF-β1, TGF-β receptors and the effectors p-Smad2/3 in the mucosa compared with control
rats. Insulin treatment attenuated the stimulating effect of diabetes on colon ECM deposition and TGF-
β/Smad signaling. In conclusion, the overall results showed a deregulation of the TGFβ1 pathway 
associated with the appearance of myofibroblasts and the accumulation of ECM in the mucosa of diabetic 
colon. These data provide the first in vivo evidence that TGF-β1/Smad is a key component of intestinal 
tissue remodeling in diabetes. 
Key words: Diabetes, colon, extracellular matrix, myofibroblasts, MMPs, TGF-β1. 
Abbreviations: FGF, fibroblast growth factor; BMP, bone morphogenetic protein; EGF, epidermal 
growth factor; ECM,  Extracellular matrix; MMPs, matrix metalloproteinase; TIMPs, metalloproteinase 
tissue specific inhibitors; TGF-β, transforming growth factor- β; TGF-βR, transforming growth factor- β 
receptor.  
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1. Introduction
Diabetic gastroenteropathy is a highly heterogeneous and often an unpredictable diabetic complication. Its 
multiple symptoms as gastroesophageal reflux, dyspepsia, abdominal pain, diarrhea, constipation or fecal 
incontinence, affect more than 75% of patients, with a profound impact on their quality of life (Camillieri. 
2002; Shakil et al., 2008). 
While at present the identification of the diabetic bowel dysfunction are common due to the accessible 
methods for diagnosis, the investigation concerning the cellular and molecular mechanisms involved in 
the pathobiology of this complication is scarce. Prior studies have proposed altered intrinsic and extrinsic 
innervations of the lower gastrointestinal tract, as main responsible for the disturbances in motility, 
sensation, secretion, and absorption (He, 2001, Yoneda et al., 2001; Furlan et al., 2002; Honoré et al., 
2011). However, a deeper biochemical and histomorphological changes seems to occur in the 
gastrointestinal tract with the progress of disease (Sanchez et al., 2001; Zhao et al., 2013; Dorfman et al., 
2015). In this regard, impaired function of intestinal barrier was observed in type 1 diabetes patients and 
in animal models (Zanoni et al., 2008). Several reports have shown that diabetes can also alter the 
behavior of many drugs due to alterations in functional proteins as the intestinal epithelial transporters 
(Ogata et al., 2014). On the other hand, it is well known that insulin is required for the maintenance of a 
normal protein synthesis in the intestinal mucosa, required for the remodeling process of this fast turning 
over tissue. Thus, insulin deprivation in diabetes may be a contributing factor in the development of 
gastrointestinal complications (Haeusler et a., 2017). 
Extracellular matrix (ECM) plays an active role in the maintenance and remodeling of tissues structure, 
being responsible for regulating numerous cellular processes such as proliferation, differentiation and 
migration (Hynes, 2009; Ahmed and French-Constant, 2016). ECM remodeling is a critical process 
during morphogenesis and tissue growth. Perturbation of its function has been implicated in pathological 
process. Under physiological conditions the normal turnover of ECM is regulated by many factors 
(growth factors, cytokines, chemokines, and proteolytic enzymes, among others) that ensure a delicate 
balance between synthesis and degradation process (Hyun-Jeong and Parks, 2007). The switch-over of 
this balance may conduct to excessive deposition of ECM with relevant clinical implications (Verrecchia, 
2007). Particularly at intestinal level, several types of cells such as epithelial, resident mesenchymal cells 
(fibroblasts, myofibroblasts and smooth muscle cells) or marrow-derived stem cells can contribute to 
produce ECM proteins (Pucilowska et al., 2000; Andoh et al., 2007). Many factors like TGF-β, activins, 
EGF are able to activate the production of ECM in these cells (Mott and Werb, 2004; Verrecchia, 2007). 
On the other hand, ECM degradation is regulated by the enzymatic activity of a group of calcium-
activated and zinc-dependent endopeptidases, the matrix metalloproteinase (MMPs) and their tissue 
specific inhibitors (TIMPs) (Clark et al., 2008; Brew and Nagase, 2010). 
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TGF-β family comprises multifunctional cytokines which regulate diverse cellular functions such as 
growth, adhesion, migration, apoptosis, differentiation and extracellular matrix synthesis (Massagué and 
Gomis, 2006; Massagué, 2008). Active TGF-β signaling is transmitted through two types of 
transmembrane serine/threonine protein kinase receptor: TGF-β type I (TGF-βRI) and TGF-β type II 
(TGFβRII) (Kang et al., 2009). TGF-β first binding to TGF-βRII leads to heterotetrameric complex 
formation with the consequent TGF-βRI phosphorylation (Massagué, 2008; Kang et al., 2009). Activated 
TGF-βRI propagates intracellular signaling by recruiting and phosphorylating receptor-regulated Smad 
(R-Smad) proteins. Activated Smads form a complex with the common Smad (Smad4) which is 
translocate into the nucleus to regulate gene expression by binding to regulatory promoter DNA alone or 
interacting with other transcription factors (Ross and Hill, 2008). 
Although high glucose is known to stimulate matrix synthesis in a variety of cell types, the participation 
of the ECM in diabetic enteropathy has not been fully understood. In this study, we evaluated the effects 
of diabetic environment in colon mucosa remodelling and examined the role of TGF-β/Smad signaling in 
these events. Additionally, we also examined the possible therapeutic action of insulin on diabetic gut. 
The knowledge of cellular and molecular changes in diabetic colon could give valuable information not 
only from a mechanistic point of view but also in the clinical context about the intestinal damage related 
to diabetes. 
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2. Methods
2.1 Animals 
Male Wistar rats of 12 weeks old and with weights comprised between 250 and 300 g were used in this 
study. Rats were maintained throughout the experimental period under controlled conditions of 
temperature (20-24°C), humidity (40-70%) and standard conditions of photoperiod (12 h of light/12 h 
darkness) with free access to food and water. All the experiments were conducted in agreement with the 
Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources, 
Commission on Life Sciences, National Research Council, National Academy Press, Washington, DC), 
and the local Institutional Animal Care Committee. 
2.2 Streptozotocin-induced diabetes 
Diabetes was induced by a single intraperitoneal injection of streptozotocin (Sigma, St Louis, USA) 
(50 mg/kg body weight), freshly dissolved in 0.05 M sodium citrate, pH 4.5. Control animals were 
injected with the vehicle alone. Diabetic state was confirmed by measurement of tail blood glucose with a 
glucometer Accu-chek® Active (Roche Diagnostics GnbHD-68298 Mannhein, Germany). Only animals 
with glucose levels ≥ 300 mg/dl were included in the study. 
2.3 Experimental design 
Rats were then divided into six groups: (i) 4 weeks normal group (N4, n = 6), (ii) 4 weeks diabetic group 
(DM4, n = 6), (iii) 4 weeks insulin-treated diabetic group (DM+I4, n=6), (iv) 9 weeks normal group (N9, 
n = 6), (v) 9 weeks diabetic group (DM9, n = 6), and (vi) 9 weeks insulin-treated diabetic group (DM+I9, 
n=6). The DM+I groups received daily insulin (5-10mUI of Insulin/b.w., Betasint), subcutaneously, to 
maintain serum glucose level at 80 to 160 mg/dl. Weekly checks were performed to assess blood glucose 
levels as well as body weight in all experimental plots. At the end of the experiment, rats were deprived 
of food for 24 h and killed by cervical dislocation at 4 or 9 weeks after diabetes induction. 
2.4 Tissue sampling 
Proximal colon was dissected from the different groups of rats. The first centimeter close to the cecum 
was removed. From this point three pieces of proximal colon (1 cm) were cut and pinned down flat onto a 
glass dish with Sylgard silicone coating. The segments of colon were rinsed with ice-cold phosphate-
buffered saline (PBS; pH 7.4) and immersed in fixative overnight at 4°C for classical histology and 
immunohistochemistry assays. The mucosa samples were obtained scraping off some segments using a 
glass slide and then stored at 80°C for further gene analysis. 
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2.5 Biochemical analyses 
Blood glucose was determined by using an Accu-chek Active tester (Roche Diagnostics GnbHD-68298 
Mannhein, Germany) based on glucose dye oxido-reductase mediator reaction. 
Plasma insulin was measured using an Enzyme-linked immunosorbent assay (Rat/mouse Insulin ELISA 
kit, Linco Research, Inc.) according to the manufacturer´s protocol. Glycated Hemoglobin A1c (HbA1c) 
was isolated by a chromatographic method using a cationic exchange resin (Hemoglobin A1c Kit, 
BioSystem S.A, Barcelona-Spain) and quantified by spectrophotometrically at 415 nm. Urinary glucose 
was determined with Micral-Test II (Boheringer Mannheim GmbH, Mannheim, Germany) reactive strips. 
 
2.6 Histology and Immunohistochemistry 
Intestinal tissue was fixed overnight in 4% formaldehyde in phosphate-buffered saline, embedded in 
paraffin and sectioned in 4 μm slices. Sections were stained with H&E for histological study, and Sirius 
red for the analysis of extracellular matrix. Picrosirius red stained sections were viewed using an 
Olympus BX80 microscope with polarization optics. The polarization birefringence colors were a 
measure of the collagen type, with a clear distinction from collagens type I (red) and type III (green). 
Immunohistochemistry was performed as was described previously (Honoré et al, 2011). Briefly, tissue 
sections were deparaffinized and the slides were immersed in 10 mM citrate buffer (pH 6.0) and treated 
with microwave radiation to unmask binding epitopes prior to antibody staining. The slides were then left 
to stand for 10 min in buffer at room temperature before being thoroughly washed in tap water. Then they 
were treated with 3% (v/v) H2O2 for 5 min, blocked with 10% (w/v) normal goat serum for 1 h, and then 
incubated with primary antibodies (see Table 1), at 4°C overnight. Slides were then incubated with 
appropriate biotin-conjugated secondary immunoglobulin G and treated with streptavidin-peroxidase 
(Sigma). Color was developed by incubating with diaminobenzidine and counterstaining with 
hematoxylin. Negative control included omission of the primary antibody. All secondary antibodies were 
confirmed to be species-specific for their individual primary antibody and mismatched secondary 
antibody. The staining was not observed in the negative controls. Semiquantitative analysis of the 
percentage of positive staining was evaluated by a computer imaging analysis system using the Image J 
software (NIH Image). Brown areas were judged as positive. All scoring was performed in a blinded 
manner on coded slides using an Olympus BX80 microscope. 
 
2.7 Reverse-Transcription Polymerase Chain Reaction (RT-PCR) 
Total RNA was isolated from colon tissue using the Illustra RNAspin Mini Kit reagent (GE Healthcare) 
according to the manufacturer’s protocol. 1μg RNA was reverse transcribed into first-strand cDNA using 
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M-MLV Reverse Transcriptase (Promega) and oligo (dT) primers (Invitrogen). The expression of 
related genes was evaluated using on a Mastercycler personal instrument (Eppendorf, Germany). 
PCR was performed in optimized conditions: 95°C denatured for 10 s followed by 30 cycles of 5 s at
95°C, 5 s at 58°C and 35 s at 72°C and one cycle of 15 s at 95°C. Specific PCR primers were designed 
from rat sequences available in the databanks: collagen type I, α1 (NM053304.1) forward primer 5’-
ACTGGCAACCTCAAGAAGTCCC-3’  and reverse primer 5’-AAGTTCCGGTGTGACTCGTGC-3’ ; 
collagen type III, α1 (NM032085.1) forward primer 5’- ACGCAAGGCCATGAGACTCC-3’  and reverse 
primer 5’-GCAAACAGGGCCAATGTCCA-3’; fibronectin 1 (NM019143.2) forward primer 5’-
CAGTTGGTTGCCCTGTTCTGC-3’  and reverse primer 5’-TCATTGCATCGTGGTTGGCTACC-3’ ; 
smooth muscle alpha actin (α-SMA) (NM031004.2) forward primer 5’-CCCGCTCTGTCTCTAGCAC-3’
and reverse primer 5’-CACACGAGTAACAAATCAAAGC-3’;  MMP-1 (NM001134530.1) forward
primer 5’-GAGGAGGGTCAACAGAGGAGC-3’ and reverse primer 5’-
AACCCCAAAACCAAAGCAGCAATG-3’; MMP-2 (NM031054.2) forward primer 5’-
TCAAATCGGACTGGCTGGGC-3’  and reverse primer 5’-AACCAGGCCTCTTCACGTCC-3’; MMP-
9 (NM031055.1) forward primer 5’-GAGGGGGAGGAGCTAGTTTGCC-3’  and reverse primer 5’-
AAGGACAGCGTGCAGAGAGGG-3’; TIMP-1 (XM006256608.1) forward primer 5’-
GATTCGACGCTGTGGGAAATGCC-3’  and reverse primer 5’-GATGAGAAACTCCTCGCTGCGG-
3’;  TIMP-2 (NM021989.2) forward primer 5’-TGAATGGAAGCCCTCCCTGAGC-3’  and reverse 
primer 5’-TACGAGGACAGCCAAGCACCC-3’; TGF-β1 (NM021578.2) forward primer 5’-
GTGGCTGAACCAAGGAGACG-3’  and reverse primer 5’-GGTGTTGAGCCCTTTCCAGG-3’; TGF-
βRI (NM012775.2) forward primer 5’-ACCGCGTACCAAATGAAGAG-3’  and reverse primer 5’-
TGTAGCACAATGGTCCTTGC-3’; TGF-βRII (NM031132.3) forward primer 5’-
AGTTTTGCGACGTGACACTG-3’  and reverse primer 5’-GGCATCTTCCAGAGTGAAGC-3’; β- 
actin (NM007393) forward primer 5’-CCGGCTTCGCGGGCGACG-3’  and reverse primer 5’- 
TCCCGGCCAGCCAGGTCC-3’.  A negative control was performed using total RNA for each gene 
analyzed. The mRNA levels were standardized against β-actin mRNA levels. The mean value for the 
control animals was set at 100%. 
2.8 SDS-PAGE Western Blot 
Colon was dissected and immediately frozen and stored at -70ºC until use. Intestinal mucosa were 
homogenized in buffer (Tris-HCL 50mM pH: 7.4; NaCl 0,1M; Nonidet P-40 1%) supplemented with 
protease inhibitors (Halt protease inhibitor, cocktail kit, Pierce), EDTA, and imidazole (Invitrogen, CA, 
USA). Protein concentration was measured applying Lowry’s method (Lowry and Rosenbrouah, 1951). 
Samples containing 80μg of protein were mixed with loading buffer (Tris-HCl 0.0625M, pH 6,8; SDS 
2%; 2-mercaptoetanol 5%; Sacarose 10%; Bromophenol blue 0.002%; H₂O(d) in the ratio 1:4 and 
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electrophoresed in 7.5% polyacrylamide gels. Loaded proteins were blotted on a nitrocellulose membrane 
by electro transference (Sigma). Proteins detection was performed using specific primary antibodies 
(Table 1). 
 
2.9 Zymography 
Gelatinase activity in the samples was determined by zymography as previously described 
(Troeberg and Nagase, 2004). Briefly, samples (30µg) of proteins from colon mucosa tissue were mixed 
with sample buffer (SDS2%, bromophenol blue 0.1%, glycerol 40%, Tris-HCL pH 6.8) and 
electrophoresed in 10% sodium dodecyl sulfate SDS-polyacrylamide gels, containing 10% gelatin. Gels 
were then renaturated al room temperature 90 min in buffer containing 200mM NaCl, 5mM CaCl2, 5µM 
ZnCl2, 2.5% Triton x-100, 0.02% NaN3, and 50mM Tris-HCl pH7.5), and then incubated overnight at 
37ºC in the same buffer without Triton x-100. Gels were stained in 0.125% Coomassie blue R-250, 50% 
methanol and 20% acetic acid and stopped in 30% methanol and 10% acetic acid. Gelatinolytic activities 
were visualized as clear bands on a blue background and analyzed with the Gelanalyzer software.   
 
2.10 Statistical analysis 
The results from three independent in vivo experiments were presented as mean ±SD. The significance of 
differences was evaluated using the paired Student’s t-test. When more than one group was compared 
with one control, significance was evaluated by ANOVA followed by Tukey’s post-test. A value of 
p<0.05 was considered statistically significant. 
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3. Results
3.1 Clinical and biochemical parameters 
Table 2 shows the biochemical characteristics of the studied animals. Diabetes significantly increased 
blood glucose and glycated hemoglobin and decreased plasma insulin levels at 4 or 9 weeks compared to
the age matched controls (p<0.05). Insulin treatment slightly improves the percentage of glycatedhemoglobin in DM+I rats at 4 and 9 weeks.  
3.2 Intestinal parameters 
The body weight of diabetic rats significantly decreased compared with normal and insulin-treated 
diabetic rats along the experimental period (p<0.05). In addition, a significant increase in total length and 
weight of the colon in diabetic animals compared to those of the control group, was observed at short or 
long term. The hypertrophy index, measured as the ratio of colon weight / body weight was increased in 
diabetic animals from both experimental periods (p<0.05) (Table 3). 
3.3 Structural alterations in diabetic colon mucosa 
Microscopic examination of diabetic colon sections showed qualitative changes in the mucosa layer 
compared with normal and insulin-treated diabetic rats. Morphometric analysis revealed a significant 
increase in crypt deep and in the thickness of the mucosa layer of the DM4 and DM9 animals compared 
to normal animals (p<0.05). Furthermore, an important cellular infiltrate in the lamina propria of the 
mucosa of DM9 and DM+I9 animals could be observed. 
Examination of tissue sections stained with Sirius red (Fig. 1A) evidenced the presence of collagen as a 
thin line located in the base of the crypts epithelium and also in the connective tissue of the colon 
submucosa in N4 and N9 rats (a and d respectively). Interestingly a sharp increase in the affinity for the 
dye was observed as dense patches of collagen fibers in basal lamina and connective tissue surrounding 
the crypts in diabetic animals (b and e). The insulin treatment restored the staining patterning DM+I4 
animals, but not in DM+I9 (f and c respectively). Quantitative analysis of serial sections confirmed the 
increase of total collagen content in DM4 (2.3-fold) and DM9 (2.5-fold) samples, compared to normal 
groups (Fig. 1B) (p<0.05). This increment was mainly due to collagen I at 4 weeks and to both types of 
collagen (I and III) at 9 weeks. Insulin treatment prevents collagen accumulation in DM+I4 mucosa. 
However, non-significant changes in the relative amount of collagen I was observed in DM+I9 respect to 
DM9 (p>0.05) (Fig. 2). 
3.4 ECM synthesis in diabetic colon mucosa 
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To understand the ECM remodeling in the mucosa layer during diabetes, we examined synthesis and 
degradation process. RT-PCR analysis demonstrated that the collagen I, III and fibronectin mRNA levels 
were significantly higher in DM4 (mean 1.8-fold, 1.3-fold and 1.5-fold respectively) than in N4 samples 
(Fig. 3A) (p<0.05). Moreover, the expression of these mRNAs increased more in DM9 colons (mean 
collagen I: 2.3-fold; collagen III: 1.7-fold and fibronectin: 2.8-fold respectively) (p<0.05) (Fig. 3B). 
Insulin treatment restored the expression levels of the mRNAs of these matrix proteins in DM+I groups 
showing a pattern similar to normal. However, it is important to note that DM+I9 animals maintained a 
high amount of fibronectin mRNA (p<0.05) (Fig. 3B).  
 
3.5 ECM degradation in diabetic colon mucosa 
Since ECM remodeling is modulated by the action of different MMPs and their TIMPs, we also 
investigated these molecules. RT-PCR analysis evidenced non-significant changes in MMP-1 mRNA 
expression in the mucosa in all analyzed groups at 4 weeks (p>0.5). However, MMP-2 and MMP-9 
mRNA levels were significantly higher in DM4 (mean 2.3-fold and 1.8-fold) than in N4 and DM+I4 
samples (p<0.05) (Fig. 4A).  
At 9 weeks, the mRNA expression of MMP-1 and MMP-2 increased in the mucosa of DM9 colons (mean 
2.7-fold and 0.5-fold) respect to N9 (p<0.05). Insulin treatment restored MMP-2 levels but had no effects 
on MMP-1 in DM+I9 showing relative high amounts of this mRNA (mean 2.4-fold) (p<0.05). MMP-9 
expression was similar in all studied groups (p>0.5) (Fig. 4B).  
The MMPs activities were evaluated by zymography analysis performed from mucosa homogenates of 
different experimental groups. Five of approximately 58, 79, 105, 123 y 134 kDa were detected (Fig. 5 
A). Interestingly, a significant decrease in the activities of all detected metalloproteases, were observed in 
diabetic mucosa at 4 and 9 weeks (p<0.5). Insulin treatment improved all the MMPs activities at 4 weeks, 
but the activity of 123kDa-MMP was only partially restored. At 9 weeks the activity of MMPs remains 
low and is not affected by insulin treatment (p>0.5) (Fig. 5B). Considering that MMPs activity is 
regulated by specific tissue inhibitors (TIMPs) we next investigated the expression of these molecules. 
Diabetes significantly increased TIMP-1 mRNA levels (mean 2.5-fold) (p<0.05), but only a slight 
increase of TIMP-2 transcripts in DM4 rats. No significant changes in TIMP-1 and TIMP-2 mRNA levels 
were detected at 9 weeks (p>0.05) (Fig.1S Supplementary material). 
 
3.6 Diabetes causes changes in the myofibroblasts  
We investigated myofibroblast distribution in colonic mucosa to identify the potential cellular 
mechanisms that lead to intestinal MEC remodeling in early stages of diabetes. We analyzed the 
morphology, sub-epithelial location and positive immunoreactivity for α-SMA and vimentin of these cells 
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(Fig.6 A and B). The DM4 colon showed a higher number of α-SMA+ and vimentin+ cells concentrated in 
the sub-epithelial region mainly at the base of the crypts. In contrast, only a small fraction of the cells are 
present in lamina propria of N4 colonic mucosa. A high α–SMA expression remains even at later stages 
of disease, as shown by RT-PCR (Fig. 2S Supplementary material). The proliferation studies showed a 
significant increase of Ki67⁺stained cells not only in the crypt epithelium but also in the sub-epithelial 
space around the crypts in DM4 animals, demonstrating a significant increase in proliferation rates in 
colon (30%, p<0.05) compared with N4 group (Fig. 6C). On the other hand, TUNEL analysis showed no 
significant differences in the apoptotic processes in all the experimental groups studied (p>0.05). 
3.7 Diabetes altered TGF/Smad signaling in colon mucosa 
The effect of diabetes and insulin on TGF/Smad signaling-related genes throughout the colon was 
determined using RT-PCR. As shown in Fig. 7A, diabetes resulted in a significant increase of TGF-β1 (3-
fold), TGF-βRI (7-fold), TGF-βRII (1.5-fold) mRNA levels in DM4 compared with N4 and D+I4 animals 
(p<0.05). At 9 weeks of diabetes, the mRNA expression of TGF-β1, TGF-βRI and TGF-βRII 
significantly increased (1.8-fold; 1.8-fold and 1.6-fold respectively) compared with N9 and D+I9 animals 
(p<0.05) (Fig. 8A). Interestingly, insulin treatment restored the mRNA expression of all TGF signaling 
components to normal levels (p<0.05). 
Western blot analysis showed an increased TGF-β1 (1.6-fold), TGF-βRI (1.7-fold) and pSmad2/3 (1.9-
fold) protein expression in DM4 colon mucosa, compared with N4 and D+I4 animals (p<0.05). While 
insulin treatment restored TGF-β1 and TGF-βRI expressions (p<0.05), pSmad2/3 remains increased at 4 
weeks (p>0.05) (Fig. 7 B). Interestingly the TGF-β1 ligand significantly increased in DM9 colon and 
insulin treatment did not have effect on it (Fig. 8B). 
Given that phosphorylation and nuclear translocation of TGF-βR activated p-Smads are the hallmarks of 
ongoing TGF-β signaling, we analyzed p-Smad 2/3 localization in the mucosa layer by
immunohistochemistry (Fig. 7C and 8C). In diabetic animals, p-Smad 2/3 staining was strongly detected
in crypt epithelial cells and in mesenchymal cells of lamina propria, with cytoplasmic and nuclear
localization (b). In contrast, normal animals showed only few epithelial cells with a weak nuclear staining 
at the crypts (a). Insulin treatment fails to restore normal TGF-β signaling activity (c) (Fig. 7C and 8C). 
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4. Discussion
Diabetes mellitus leads to long-term alterations that affect the functionality of various organs and
systems, including the gastrointestinal tract. Using an in vivo STZ-induced diabetic model, we
demonstrated that hyperglycemia is associated with cellular and molecular changes in the colonic 
mucosa. 
The maintenance of the normal tissue structure depends not only on a delicate balance between the
processes of cell proliferation, migration, differentiation and apoptosis but also requires the continuous
interaction of its cellular components and the ECM (Groos et al., 2001; Hynes, 2009). In the present 
study, we demonstrated that diabetic enteropathy is characterized by matrix accumulation and thickening 
of basement membrane in the colon mucosa. These changes are the result of an imbalance in the synthesis 
and degradation of ECM components, particularly type I and III collagens and fibronectin. Similar
observations were evident in the muscle layer of diabetic jejunum (Sánchez, 2000). 
We associate the increase in ECM synthesis with a significant increase of activated mesenchymal cells,
especially myofibroblasts, in the lamina propria of diabetic colon. These cells exhibit a contractile 
phenotype characterized by the expression of α-SMA and vimentin, and are capable to secrete large 
amounts of ECM (Powell et al., 2000; Sandbo and Dulin, 2011).  It has recently been suggested that 
myofibroblasts may originate from various cellular types as local fibroblast populations, activated
resident myofibroblasts, mesenchymal stem cells, and epithelial cells or through fibrocytes coming from 
the bone marrow (Hinz et al, 2012; Micallef et al., 2012). In our study the increased proliferation of 
myofibroblast detected in the lamina propria in diabetic mucosa, lead us to believe that the origin of these
cells could be from resident myofibroblasts or fibroblasts. However, the possibility that the increased 
population of myofibroblasts in the diabetic colon could have another origin is not ruled out. Similar 
alterations were found in inflammatory bowel diseases where proliferation and differentiation of
fibroblasts and myofibroblasts in the lamina propria were associated to an increased collagen deposition 
(Zorzi et al., 2015; de Souza, 2017).  
Chronic hyperglycemia not only promotes matrix formation but also decrease its degradation in several 
tissues (McLennan et al., 2002). MMPs are endopeptidases that are responsible for degrading MEC
molecules, thus taking part in the regulation of physiological and pathological processes (Hyun-Jeong and 
Parks, 2007). There are at least 25 types of these enzymes (Kirkegaard et al., 2004). Among them, MMP-
1, MMP-2 and MMP-9 have been associated with MEC remodeling processes in different organs 
(Giannandrea and Parks, 2014). Our results showed an increased expression early on gelatinases MMP-2, 
MMP-9 mRNAs and later in the collagenase MMP-1, in the diabetic colon mucosa. In line of this, it has
been shown that myofibroblasts secrete MMP-2 and, upon stimulation, MMP-1, -3 and -9 having an 
active role in tissue remodeling during intestinal inflammation (McKaig et al., 2003; Kirkegaard et al., 
13 
2004).  Infiltrating macrophages and neutrophils were seen to be a major source of MMP-9 in human 
intestinal bowel disease and a mouse model of colitis in intestinal inflammation (Medina and Radomski, 
2006) whereas MMP-1 is mainly produced by epithelial cells in response to inflammatory stimuli (Gao et 
al., 2005).  In spite of transcriptional MMPs upregulation, low net matrix degrading activity in diabetic 
colon mucosa was observed by zymography. The enzymatic activity of the MMPs can be silenced by 
specific inhibitors of metalloproteases (TIMP1, 2, 3 and 4) which act by forming a 1:1 inactive complex, 
unable to bind substrate (Clark et al., 2008). In this work we find an increased expression of TIMP-1 and 
TIMP-2 which could result in decreased MMPs activities observed in diabetic colon mucosa. In addition, 
glycation of matrix components could affect the activities of the MMPs and thereby mediate indirectly 
some of the effects of chronic hyperglycemia, as was suggested by (McLennan et al., 2002). 
The ECM has been also considered a source of inactive growth factors and other bioactive molecules 
which play an essential role in the overall matrix contribution to tissue homeostasis. These bound inactive 
factors could become unleashed upon matrix degradation initiatiating growth factor receptor signaling 
(Yu and Stamenkovic, 2000, Mott and Werb, 2004). In this sense, fibronectin-bound latent form TGF-β is 
released to its active form in the presence of MMP-2 and MMP-9 (Yu and Stamenkovic, 2000). Recently, 
other studies reported that MMP-9 expression is positively related to events that promote excessive 
accumulation of ECM, through the regulation of TGF-β1 expression (Krstic and Santibanez, 2014). 
Moreover, it has been shown that collagen and fibronectin are able to activate an integrin-dependent, 
transforming growth factor (TGF)-β/Smad signaling, independently of TGF-β or TGF-βR (Garamszegi et 
al., 2010). Theses findings further enhance the contribution of ECM modulation on cellular behavior.  
Bearing these factors in mind, we therefore analyzed the possible involvement of TGF-β1/Smads pathway 
in diabetic colon mucosa. It is known that this signaling pathway is active in the gastrointestinal tract 
where it plays a critical role in intestinal homeostasis (Walters, 2005). In this regard we analyzed the 
expression of different components of this pathway. In experimental diabetes we observed a significant 
increase in the expression of both mRNA and protein TGF-β1 in the mucosa layer. Recent studies have 
linked high levels of TGF-β1 involved in the degenerative alterations that develop in the course of 
different intestinal pathologies such as Crohn's disease and in ulcerative colitis (Sedda et al., 2015; Zorzi 
et al., 2015). Similar results were observed in other experimental models of chronic inflammation of the 
rodent intestine (Lawrance et al., 2003). 
Several lines of evidence suggest that chronic inflammation may promote excessive accumulation of 
ECM in tissues, triggering the onset of a fibrotic process and involvement of disease progression 
(Verrecchia and Mauviel, 2007; Hinz et al; 2012). As mentioned above, our results showed that the 
diabetic intestine is in an inflammatory microenvironment with an increased ECM deposition of collagen 
and fibronectin, concomitant with an activated TGF-β1 pathway. This situation allows us to suggest that 
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diabetes, could lead to a fibrogenic process in the gut taking into account that fibrosis is a chronic and 
progressive process characterized by excessive deposition of ECM components, particularly type I and III 
interstitial collagen (Pohlers et al., 2009; Hinz et al; 2012). Fibrotic lesions affect all organs and can result
in disruption of the structure and affect their function (Verrecchia and Mauviel, 2007, Giannandrea and
Parks, 2014).  
Many in vitro studies have suggested that high levels of glycemia lead to increase non-enzymatic 
glycation of proteins, de novo synthesis of diacylglycerol and subsequent activation of protein kinase C, 
characteristic of the diabetic microenvironment, increasing the production of TGF-β and other cytokines- 
(Chen et al., 2012). On the other hand, it has been determined that in damaged tissues TGF-β1 can also be
produced by immune cells, epithelial cells and/ or parenchymal cells (Hinz et al., 2012). It is probable that
the inflammatory cells present in the lamina propria and submucosa of diabetic colons could be partially
responsible for the increased production of TGF-β1 in the intestine, as was observed in other pathologies
(Andoh et al., 2007; Sans and Masamunt, 2006). In addition, there is experimental evidence that once 
activated, myofibroblasts also contribute to the production of TGF-β, so that they participate in the
synthesis of MEC proteins as well as paracrine and autocrine factors mediating the fibrotic response 
(Andoh et al., 2007; Brenmoehl et al., 2009; Pohlers et al., 2009). 
As we mentioned previously, TGF-β1-mediated activation induces the translocation of the Smad2/3-
Smad 4 complex into the cell nucleus, where it directly promotes the expression of the white genes. By
the end of 2000, 12 genes were known to contain Smads-regulated regions, including ECM molecules 
such as COL1A1 (Jimenez et al., 1994). Subsequently, by microarray studies the list was increased
including white genes like COL3A1, COL5A2, COL6A3 and TIMP-1 (Verrecchia and Mauviel, 2007).  
Recent evidence suggests that Smad2/3 could also be activated by JNK, in the fibrotic process (Grynberg 
et al., 2017) suggesting that diabetes provides a complex metabolic environment of hormones, growth 
factors, and metabolic factors which may contribute to the pathogenesis of matrix accumulation. 
In fact, all of the above-mentioned information allows us to conclude that TGF-β1-mediated signaling 
would be involved in the remodeling of the mucosa layer in diabetes. This proposal is based on the fact
that TGF-β1, as mentioned above, activates myofibroblasts and induces the synthesis and accumulation of 
collagen in tissues. It inhibits its degradation through the increase of protease inhibitors and the 
suppression of proteolytic enzymes (Pucilowska et al., 2000; Giannandrea and Parks, 2014). NK directly 
phosphorylates SMAD3 to enhance transcription of pro-fibrotic molecules 
In sum, our results suggest that ECM accumulation in diabetic enteropathy is predominantly mediated by
hyperglycemia. However, we do not exclude any possible direct effect of insulin on the mechanism in 
matrix protein synthesis, as was suggested by diabetic nephropathy (Cao and Cooper, 2011). In addition,
our results showed that insulin treatment could also modulate ECM degradation through MMPs activities
which is relevant to increase matrix protein accumulation in diabetic intestine. The improvements of
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insulin treatment for diabetes-induced colon mucosa changes observed at 4-weeks, seems to be less
effective with the progression of disease. Probably, despite strict glycemic control, variations in normal 
blood glucose levels may eventually occur as could be inferred from glycosylated hemoglobin levels. 
Thus, high glucose induced intracellular reactive oxygen species (ROS) and/or advanced glycosylation 
end product’s accumulation could contribute to progressively alter the structure and function of proteins
(such as collagen and fibronectin) in the intestinal wall during this hyperglycemia periods (Chen et al., 
2012).  
Together, our data provide the first in vivo evidence that TGF-β1/Smad is a key component of tissue-
specific remodeling in diabetes associated with decreased turnover of ECM.
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FIGURE LEGENDS 
Figure 1. Effect of diabetes on intestinal ECM. A. Representative sections of colon mucosa of normal, 
diabetics and insulin treated-diabetic rats at 4 (a-c) and 9 (d-f) weeks of disease stained by Sirius red. 
Scale bar: 50µm (a-c) 100µm (d-f). B: Densitometric analysis of the stained sections. The mean values ± 
SD of three experiments are expressed as a percentage of control.  N, normal control rats; DM, diabetic 
rats; DM+I, insulin treated diabetic; ep, epithelium; lp, lamina propria; cc, globet cell; cl, Lieberkühn 
crypt. a p< 0.05 DM and DM+I versus N; b p< 0.05 DM+I versus DM. 
Figure 2. Effect of diabetes on the relative amounts of intestinal collagens. A. Representative sections 
of of Sirius red stained samples of colon mucosa of normal, diabetics and insulin treated-diabetic rats at 4 
and 9 weeks of disease analyzed by Polarized microscopy. Scale bar: 50µm. B: Densitometric analysis of 
the stained sections. The mean values ± SD of three experiments are expressed as a percentage of control. 
N, normal control rats; DM, diabetic rats; DM+I, insulin treated diabetic; ep, epithelium; lp, lamina 
propria; cc, globet cell; cl, Lieberkühn crypt. a p< 0.05 DM and DM+I versus N; b p< 0.05 DM+I versus 
DM. 
Figure 3. Effect of diabetes on intestinal ECM synthesis. A: RT-PCR analysis of type I and III 
collagen and fibronectin gene expression from samples obtained from colon mucosa of normal, diabetics 
and insulin treated diabetic rats at 4 weeks of disease. The mean values ± SD of three experiments 
expressed as a percentage of control are shown with representative gels. B: RT-PCR analysis of type I 
and III collagen and fibronectin gene expression from samples obtained at 9 weeks of disease. The mean 
values ± SD of three experiments expressed as a percentage of control are shown with representative gels. 
N, normal control rats; DM, diabetic rats; DM+I, insulin treated diabetic; M, molecular weight marker; (-) 
negative control.  a p< 0.05 DM and DM+I versus N; b p< 0.05 DM+I versus DM.  
Figure 4. Effect of diabetes on intestinal MMPs expression. A: RT-PCR analysis of MMP-1, MMP-2 
and MMP-9 gene expression from samples obtained from colon mucosa of normal, diabetics and insulin 
treated diabetic rats at 4 weeks of disease. The mean values ± SD of three experiments expressed as a 
percentage of control are shown with representative gels. B: RT-PCR analysis of the same MMPs at 9 
weeks of disease. The mean values ± SD of three experiments expressed as a percentage of control are 
shown with representative gels. N, normal control rats; DM, diabetic rats; DM+I, insulin treated diabetic; 
M, molecular weight marker; (-) negative control. a p< 0.05 DM and DM+I versus N; b p< 0.05 DM+I 
versus DM. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
21 
 
 
Figure 5. Effect of diabetes on colon mucosa MMPs activity. A: Representative zymogram results 
obtained from colon mucosa of normal, diabetics and insulin treated diabetic rats at 4 and 9 weeks of 
disease. B: Densitometric analysis of the detected bands. The mean values ± SD of three experiments 
expressed as a percentage of control are shown with representative gels. a p< 0.05 DM and DM+I versus 
N; b p< 0.05 DM+I versus DM. 
 
Figure 6. Effect of diabetes on mucosa myofibroblast markers and proliferation. Immunostaining of 
α-SMA (A) and Vimentin (B) in colon mucosa of normal and diabetics rats at 4 weeks of disease. Scale 
bar: 50µm. The mean values ± SD of three experiments expressed as a percentage of control. C: 
Immunostaining of Ki67 in colon mucosa of normal and diabetics rats at 4 weeks of disease. Scale bar: 
50µm.  The mean densitometric values ± SD of three experiments expressed in arbitrary units. N, normal 
control rats; DM, diabetic rats; DM+I, insulin treated diabetic; M, molecular weight marker; (-) negative 
control; ep, epithelium; lp, lamina propria; cc, globet cell; cl, Lieberkühn crypt. a p< 0.05 DM and DM+I 
versus N; b p< 0.05 DM+I versus DM.  
 
Figure 7. Effect of early diabetes on intestinal expression of TGF-β/Smad signaling. A: RT-PCR 
analysis of TGF-β/Smad-related gene expression from samples obtained from colon mucosa of normal, 
diabetics and insulin treated diabetic rats at 4 weeks of disease. B: Representative results of Western blot 
analysis of TGF-β1, TGF-βRI and p-smad 2/3 obtained from corresponding samples. C: Immunostaining 
of p-smad 2/3 in intestinal mucosa. Note nuclear staining (arrows) in diabetic colons. Scale bar: 50µm.  
Insert magnification: 40X. The mean values ± SD of three experiments expressed as a percentage of 
control.  N, normal control rats; DM, diabetic rats; DM+I, insulin treated diabetic; M, molecular weight 
marker; (-) negative control; ep, epithelium; lp, lamina propria; cc, globet cell; cl, Lieberkühn crypt. a p< 
0.05 DM and DM+I versus N; b p< 0.05 DM+I versus DM.  
 
Figure 8. Effect of late diabetes on intestinal expression of TGF-β/Smad signaling. A: RT-PCR 
analysis of TGF-β/Smad-related gene expression from samples obtained from colon mucosa of normal, 
diabetics and insulin treated diabetic rats at 9 weeks of disease. B: Representative Western blot of TGF-
β1 protein. C: Immunostaining of p-smad 2/3 in intestinal mucosa. Note nuclear staining (arrows) in 
diabetic colons. Scale bar: 50µm.  Insert magnification: 40X. The mean values ± SD of three experiments 
expressed as a percentage of control. N, normal control rats; DM, diabetic rats; DM+I, insulin treated 
diabetic; M, molecular weight marker; (-) negative control; ep, epithelium; lp, lamina propria; cc, globet 
cell; cl, Lieberkühn crypt.  a p< 0.05 DM and DM+I versus N; b p< 0.05 DM+I versus DM. 
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APPENDIX A. SUPPLEMENTARY DATA  
Figure 1S. Effect of diabetes on the intestinal TIMPs expression. A. RT-PCR analysis of TIMP-1 and 
TIMP-2 gene expression from samples obtained from colon mucosa of normal, diabetics and insulin 
treated-diabetic rats at 4 and 9 weeks of disease. B: RT-PCR analysis of same TIMPs at 9 weeks of 
disease. The mean values ± SD of three experiments expressed as a percentage of control are shown with 
representative gels. N, normal control rats; DM, diabetic rats; DM+I, insulin treated diabetic; M, 
molecular weight marker; (-) negative control. a p< 0.05, significantly different from control; b p< 0.05, 
significantly different from diabetic. 
Figure 2S. Effect of diabetes on intestinal α-SMA expression. A. RT-PCR analysis of α-SMA gene 
expression from samples obtained from colon mucosa of normal, diabetics and insulin treated diabetic 
rats at 4 weeks of disease. B: RT-PCR analysis at 9 weeks of disease. The mean values ± SD of three 
experiments expressed as a percentage of control are shown. N, normal control rats; DM, diabetic rats; 
DM+I, insulin treated diabetic; M, molecular weight marker; (-) negative control. a p< 0.05 DM and 
DM+I versus N; b p< 0.05 DM+I versus DM. 
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Table 1 
Antibodies used. 
 Host Dilution* Catalogue no. Source 
Primary antibody     
α-SMA Mouse 1:100  A2547 Sigma 
Vimentin  Goat 1:100  V4630  Sigma 
Ki-67  Rabbit 1:100 AB9260 Millipore 
TGF-β1 Rabbit 1:50 sc-146 Santa Cruz Biotech 
TGF-β receptor I  Rabbit 1:50  Sc-400  Santa Cruz Biotech 
p-Smad2/3 Goat 1:100 sc-11769 Santa Cruz Biotech 
γ-Tubulin  Rabbit 1:500  T3569  Sigma 
 
Secondary antibody 
Biot anti-goat IgG Rabbit 1:750 B7014 Sigma 
Biot anti-mouse IgG  Goat 1:750 B2010 Sigma 
Biot anti-rabbit IgG Mouse 1:250 B3275 Sigma 
ExtrAvidin®-phosphatase  1:3000 E2636 Sigma 
* Dilution used in immunohistochemical and westernblot studies. 
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Table 2 
Biochemical features of animals in study 
Blood Glucose 
(mg/dl) 
Glycated hemoglobin 
(%HbA1C) 
Plasma insulin 
(ng/ml) 
N4 118.67 ± 4.92 6.03 ± 1.48 2.39 ± 0.09 
DM4 479.00 ± 16.81a 14.49 ± 0.50a 0.35 ± 0.07a 
DM + I4 102.00 ± 25.82 8.83 ± 2.32b 0.58 ± 0.23a 
N9 113.00 ± 4.00 6.50 ± 1.28 2.03 ± 0.59 
DM9 479.25 ± 32.04a 12.96 ± 0.34a 0.41 ± 0.15a 
DM + I9 127.08 ± 29.51 9.30 ± 0.77a,b 0.71 ± 0.35a,b 
Data are mean ± SD. n=6 animals per group.  
a p< 0.05 DM and DM+I versus N; b p< 0.05 DM+I versus DM. 
Table 3 
Clinical features of animals in study 
Final body weight (g) Colon lenght (g) Ratio colon weight / body weight (%) 
N4 379.43 ± 9.43 8.25 ± 0.30 0.12 ± 0.02 
DM4 235.15 ± 47.72a,b 10.85 ± 0.40a,b 0.32 ± 0.02a,b 
DM + I4 308.80 ± 19.45a 8.25 ± 1.00 0.14 ± 0.01 
N9 456.35 ± 14.25 9.75 ± 0.75 0.18 ± 0.02 
DM9 212.30 ± 12.56a,b 12.05 ± 0.76a,b 0.54 ± 0.07a,b 
DM + I9 358.20 ± 33.16a,b 11.25 ± 0.25 0.23 ± 0.02a 
Data are mean ± SD. n=6 animals per group.  
a p< 0.05 DM and DM+I versus N; b p< 0.05 DM+I versus DM. 
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